Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Bibliographic Details
Main Authors:	Finckh, Axel, Möller, Burkhard, Dudler, Jean, Walker, Ulrich A, Kyburz, Diego, Gabay, Cem
Format:	Online
Language:	English
Published:	BMJ Group 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500530/

Similar Items

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
by: Kekow, Joern, et al.
Published: (2012)

Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist
by: Kopec-Medrek, Magdalena, et al.
Published: (2011)

Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial
by: Durez, Patrick, et al.
Published: (2014)

Seronegative and seropositive rheumatoid arthritis treated with rituximab
by: Velloso Feijoo, Maria Luisa, et al.
Published: (2012)

Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis
by: Furuya, Hidekazu, et al.
Published: (2013)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
by: Emery, P, et al.
Published: (2015)

Rituximab (RTX) as an Alternative to TNF-Alpha Antagonists in Patients with Rheumatoid Arthritis and High Risk of Severe Infections: A Systematic Analysis of the Experience in One Center
by: Xanthouli, P, et al.
Published: (2012)

Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study
by: Möller, Burkhard, et al.
Published: (2014)

TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients
by: Al-Rayes, Hannan, et al.
Published: (2011)

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
by: Hirabara, Shinya, et al.
Published: (2014)

New approaches to inhibiting TNF production in rheumatoid arthritis: is pathological TNF regulated in the same way as protective TNF?
by: Feldmann, M, et al.
Published: (2001)

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis
by: Nguyen, Dao Xuan, et al.
Published: (2016)

Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure
by: Gutierrez-Gonzalez, Luis Arturo, et al.
Published: (2013)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
by: Listing, Joachim, et al.
Published: (2015)

TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
by: Orbán, I, et al.
Published: (2011)

Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
by: Kuppen, P. J., et al.
Published: (1997)

Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
by: Marotte, Hubert, et al.
Published: (2008)

Clinical Significance of Cartilage Biomarkers for Monitoring Structural Joint Damage in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy
by: Niki, Yasuo, et al.
Published: (2012)

Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα
by: Castro-Villegas, Carmen, et al.
Published: (2015)

Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
by: Hernández-Cruz, Blanca, et al.
Published: (2016)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
by: Said, Cynthia, et al.
Published: (2013)

The Role of TNFα in the Pathogenesis of Rheumatoid Synovitis
by: Maini, Ravinder N, et al.
Published: (2000)

Bone and TNF in rheumatoid arthritis: clinical implications
by: Manara, Maria, et al.
Published: (2015)

Association of the A Allele of the TNF-Alpha-308 G/A Gene Polymorphism with Radiographic Progression in Rheumatoid Arthritis
by: Stojanović Sonja, et al.
Published: (2018-03-01)

Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α
by: Puertas-Abreu, Eduardo, et al.
Published: (2012)

Protective effect of resveratrol on TNF-α-treated vascular endothelial cells
by: Xu, Jingyu, et al.
Published: (2012)

Induction of Apoptosis in TNF-Treated L929 Cells in the Presence of Necrostatin-1
by: Sawai, Hirofumi
Published: (2016)

An anti-TNF-α antibody mimetic to treat ocular inflammation
by: Khalili, Hanieh, et al.
Published: (2016)

The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug
by: Navarro Coy, Nuria C, et al.
Published: (2014)

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists
by: Navarro-Sarabia, Federico, et al.
Published: (2009)

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
by: Carmona, Loreto, et al.
Published: (2006)

Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists
by: Germano, Valentina, et al.
Published: (2014)

Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis – A Population-Based Cohort Study
by: Fisher, Anat, et al.
Published: (2014)

Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension
by: Trebicka, Jonel, et al.
Published: (2013)

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy
by: Chen, Der-Yuan, et al.
Published: (2011)

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
by: Bykerk, Vivian P, et al.
Published: (2012)

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
by: Genovese, Mark C, et al.
Published: (2014)

Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies
by: Beigel, Florian, et al.
Published: (2014)

Physiologic role of interleukin-1 receptor antagonist
by: Arend, William P, et al.
Published: (2000)

In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis
by: Meusch, Undine, et al.
Published: (2015)